Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Gross Margin: 2020-2025

Historic Gross Margin for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to 85.22%.

  • Xeris Biopharma Holdings' Gross Margin rose 1026.00% to 85.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 84.56%, marking a year-over-year increase of 320.00%. This contributed to the annual value of 81.86% for FY2024, which is 66.00% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Gross Margin stood at 85.22% for Q3 2025, which was up 2.22% from 83.37% recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Gross Margin high stood at 85.48% for Q1 2025, and its period low was 62.01% during Q2 2021.
  • Moreover, its 3-year median value for Gross Margin was 83.79% (2024), whereas its average is 82.95%.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Gross Margin soared by 2,363bps in 2021, and later crashed by 808bps in 2024.
  • Over the past 5 years, Xeris Biopharma Holdings' Gross Margin (Quarterly) stood at 77.19% in 2021, then surged by 383bps to 81.02% in 2022, then spiked by 193bps to 82.95% in 2023, then skyrocketed by 128bps to 84.23% in 2024, then skyrocketed by 1,026bps to 85.22% in 2025.
  • Its Gross Margin was 85.22% in Q3 2025, compared to 83.37% in Q2 2025 and 85.48% in Q1 2025.